Module 9 Integrative Flashcards
Aciclovir
Aciclovir a faulty base.
Mimics the real purine, guanosine
When incorporated into the elongating DNA chain causes “chain termination”, therefore viral DNA unable to be properly synthesised
Only activated in infected cells (requires both human cellular enzymes and viral enzymes thymidine kinase to activate it into active form)
Higher affinity for viral DNA polymerase than cellular enzymes
Aciclovir: Resistance
Absence of thymidine kinase – TK- variants
Alteration of thymidine kinase – TK mutants
Altered DNA polymerase
Valaciclovir
Valaciclovir - Addition of valine tail to acyclovir to improve half life and oral bioavailability
Means less frequent dosing can be used eg twice a day rather than 5 times per day
Mimics the real purine, guanosine
When incorporated into the elongating DNA chain causes “chain termination”, therefore viral DNA unable to be properly synthesised
Only activated in infected cells (requires both human cellular enzymes and viral enzymes thymidine kinase to activate it into active form)
Higher affinity for viral DNA polymerase than cellular enzymes
Ganciclovir
Anti-cytomegalovirus drugs: Ganciclovir
Acyclic guanosine analogue
Requires phosphorylation – by the viral enzyme UL97
Ganciclovir triphosphate acts as DNA polymerase inhibitor
Active against all herpesviruses
Poorly absorbed orally – valganciclovir
Toxic eg bone marrow
Cidofovir
Anti-cytomegalovirus drugs: Cidofovir
Acyclic phosphonate nucleotide analogue
Non-viral dependent phosphorylation
Inhibits viral DNA polymerase
Broader spectrum – potentially all DNA viruses
Given by intravenous infusion
Toxicity - nephrotoxic
Foscarnet
Anti-cytomegalovirus drugs: Foscarnet
Pyrophosphate analogue
Viral DNA polymerase inhibitor
Poor oral availability
Nephrotoxic
Ribavirin
Interferes with mRNA processing
Broad spectrum of activity in vitro, incl both DNA and RNA viruses
Clinical use mostly disappointing except
Severe RSV infection
Lassa fever
Amantadine
Inhibits uncoating of influenza A virus
Effective, BUT:
Poorly tolerated because of CNS stimulation
Resistance rapidly emerges
No longer recommended
Zanamavir
Viral release inhibitors
Neuraminidase inhibitor
Work against all known influenza NA
Licensed for treatment of severe infection, or infection in high risk individuals
Resistance to oseltamivir in H5N1 ‘flu has now been reported – H275Y Still uncommon
Neuraminadases found to be effective against avian influenza strains
Disease-causing human retroviruses - which is worse
HIV-1
HIV-2
HIV-1 more potent, transmissible, is found worldwide
HIV Routes of transmission
Sexual
Homosexual – highest risk - receptive anal sex
Heterosexual - now account for roughly same number of current infections
Mother-to-baby
Antenatally: transplacental
Perinatally: in birth canal, exposure to maternal blood
Postnatally: in breast milk
Blood or blood products
Transfusion contaminated blood and blood products
IVDU
Needle-stick injury
HIV lifetime presentation
Initial increase in viral load, followed by decrease -> Seroconversion illness:
Flu like symptoms
Lymphadenopathy
Rash
As viral load increases over time:
Opportunistic infections:
- Pneumocystis pneumonia
- Oral/oesophageal candidiasis
- Herpes infection/shingles
- Cryptococcus
AIDS related cancers
- Kaposis sarcoma, cervical cancer
Wasting
Elite controllers HIV
An elite controller is a person living with HIV who is able to maintain undetectable viral loads for at least 12 months despite not having started antiretroviral therapy (ART)
Elite controllers are rare: ~ 0.5% of those infected
T cell-mediated immune responses different from other patients
AIDS CD4+ threshold
<200
HIV life cycle
HIV attachment
Reverse transcription of RNA to DNA
HIV integration
Transcription and translation
Viral release and proteases
HIV attachment - proteins involved
HIV binds to white cells including lymphocytes and macrophages which express CD4 on their surfaces. Gp120 binds to CD4 and co-recptors –CCR5 or CXCR4
PEPSE, PREP for HIV
PEPSE
Post exposure prophylaxis after Sexual exposure
Must be started within 72 hours of unsafe sex
4 weeks treatment
PREP
Pre-exposure prophylaxis
86% effective
Truvada (tenofovir/emtricitabine) once a day
Either on-demand or continuous
Requires monitoring
Common drug interactions with antivirals
Via enzyme induction of cytochrome p450 – which effects metabolism of many drugs and can cause reduction and elevation of drug levels
Eg :
Decreased Rifampicin
Increased Midazolam
Expected CD4 Counts for OI in HIV
No cut-off Kaposi’s sarcoma, Pulmonary TB, Herpes Zoster, Bact. pneumonia, Non Hodgkin’s Lymphoma
<250/ul Pneumocystis pneumonia, Oesophageal Candida, HSV, PML
<100/ul Cerebral toxoplasmosis, Cryptococcosis, Miliary TB
<50/ul CMV retinitis, Atypical mycobacteriosis
PCP (pneumocystis jirovecii) presentation diagnosis xray treatment; if not treated
History
Dyspnoea on exertion
Dry cough
Sub febrile temperature, malaise
Diagnosis
Induced sputum (Sens 50-90%)
Broncho-alveolar lavage (Sens 90%)
PCR/ Immunofluorescence/Silver stain
Xray
CXR- perihilar haze, interstitial infiltrates, sparing apices,
Treatment
Co-trimoxazole (high dose)
Pentamidine
Clindamycin and primaquine
Steroids
If not treated -> pnueuomothorax
TB - presentation diagnosis xray treatment; if not treated
History
SOB, dry cough, haemoptysis
Weight loss, night sweats, lymphadenopathy
Headache, eye symptoms, fits, focal neurology
Diagnosis
CD4 any
BAL, Induced sputum, Biopsy, CSF
Smear, PCR, T-spot test (past exposure)
CT imaging
Treatment
Quadruple therapy +/- steroids
Cryptosporidium
Protozoan parasite
Faeco-oral route transmission, contaminated water
Sub acute profuse, non bloody diarrhoea affects small intestine
Malabsorption
HAART
Paromomycin
Azithromycin
Nitazoxanide
Isosporiasis Microsporidiosis
Parasites
HIV Neurological Conditions
Presentation Main Causes
Space occupying lesions Toxoplasmosis, primary CNS
lymphoma, PML, TB, cryptococcus, NHL, syphilitic gummae
Encephalitis HIV, varicella zoster virus, herpes simplex virus, syphilis
Meningitis HIV seroconversion, cryptococcus, TB, syphilis, bacteria (strep pneumoniae)
Spastic paraparesis HIV vacuolar myelopathy, transverse myelitis – VZV/HSV/HTLV-1/toxo/syphilis
Polyradiculitis CMV, NHL